ATS 2018 International Conference - Mobile

Safety and Tolerability of ARD-3150, Inhaled Liposomal Ciprofloxacin, in Patients with Bronchiectasis and Chronic Pseudomonas Aeruginosa Infection: Results from Two Phase 3 Trials [Board No. 618]

Location: Board no. 618

Session Type: RAPiD: Rapid Abstract Poster Discussion Session

Wednesday

May

23

9:15 AM

11:15 AM

Speaker(s)/Author(s)

Charles Haworth

MD
Papworth Hosp;Papworth Hospital

Sanjay Sethi

md
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo;State University of New York at Buffalo;University at Buffalo;University at Buffalo, State University of New

Juergen Froehlich

MD, MBA, FCPh
Aradigm Corporation

Igor Gonda

PhD
Aradigm Corporation

Anne E. O'Donnell

MD
Georgetown Univ Hosp;Georgetown University;Georgetown University Medical Center

Angela M. Davis

MD
Grifols, Inc

View Abstract

Safety and Tolerability of ARD-3150, Inhaled Liposomal Ciprofloxacin, in Patients with Bronchiectasis and Chronic Pseudomonas Aeruginosa Infection: Results from Two Phase 3 Trials

Parent Sessions

D23 - ADULT CF AND NON-CF BRONCHIECTASIS...
05-23-2018 9:15 AM - 11:15 AM